MediciNova (MNOV) Competitors $1.43 +0.11 (+7.92%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.38 -0.05 (-3.85%) As of 08/1/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNOV vs. MREO, TKNO, ANNX, LFCR, MNPR, VOR, ACB, CRDF, EDIT, and ZYBTShould you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Mereo BioPharma Group (MREO), Alpha Teknova (TKNO), Annexon (ANNX), Lifecore Biomedical (LFCR), Monopar Therapeutics (MNPR), Vor Biopharma (VOR), Aurora Cannabis (ACB), Cardiff Oncology (CRDF), Editas Medicine (EDIT), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. MediciNova vs. Its Competitors Mereo BioPharma Group Alpha Teknova Annexon Lifecore Biomedical Monopar Therapeutics Vor Biopharma Aurora Cannabis Cardiff Oncology Editas Medicine Zhengye Biotechnology MediciNova (NASDAQ:MNOV) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk. Do analysts prefer MNOV or MREO? MediciNova presently has a consensus price target of $7.00, suggesting a potential upside of 389.51%. Mereo BioPharma Group has a consensus price target of $7.20, suggesting a potential upside of 333.73%. Given MediciNova's stronger consensus rating and higher probable upside, equities research analysts plainly believe MediciNova is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has preferable valuation and earnings, MNOV or MREO? MediciNova has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediciNova$1M70.14-$11.04M-$0.23-6.22Mereo BioPharma Group$10M26.39-$43.25M-$0.07-23.71 Does the media favor MNOV or MREO? In the previous week, MediciNova had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 4 mentions for MediciNova and 2 mentions for Mereo BioPharma Group. MediciNova's average media sentiment score of 1.09 beat Mereo BioPharma Group's score of 0.00 indicating that MediciNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mereo BioPharma Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in MNOV or MREO? 9.9% of MediciNova shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 13.6% of MediciNova shares are owned by insiders. Comparatively, 5.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, MNOV or MREO? MediciNova has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Is MNOV or MREO more profitable? MediciNova's return on equity of -20.77% beat Mereo BioPharma Group's return on equity.Company Net Margins Return on Equity Return on Assets MediciNovaN/A -20.77% -19.68% Mereo BioPharma Group N/A -69.33%-57.27% SummaryMediciNova beats Mereo BioPharma Group on 10 of the 15 factors compared between the two stocks. Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNOV vs. The Competition Export to ExcelMetricMediciNovaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.14M$3.01B$5.55B$9.35BDividend YieldN/A2.45%4.74%4.13%P/E Ratio-6.2217.8528.9923.78Price / Sales70.14307.17437.8995.05Price / CashN/A41.6335.0756.59Price / Book1.348.488.255.54Net Income-$11.04M-$55.06M$3.25B$259.97M7 Day Performance-2.05%-3.99%-3.75%-4.67%1 Month Performance13.49%8.53%2.99%3.29%1 Year Performance10.85%6.51%25.34%17.92% MediciNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNOVMediciNova2.7026 of 5 stars$1.43+7.9%$7.00+389.5%+10.9%$70.14M$1M-6.2210News CoverageUpcoming EarningsMREOMereo BioPharma Group1.4928 of 5 stars$1.76flat$7.20+309.1%-57.1%$279.84M$10M-25.1440TKNOAlpha Teknova2.1957 of 5 stars$5.14-0.8%$10.00+94.6%+14.0%$276.82M$37.74M-10.71240Upcoming EarningsANNXAnnexon2.2048 of 5 stars$2.49-0.8%$12.50+402.0%-59.0%$275.38MN/A-2.1160Gap DownLFCRLifecore Biomedical1.4779 of 5 stars$7.33-1.3%$8.00+9.1%+24.6%$275.10M$128.26M-5.06690News CoverageMNPRMonopar Therapeutics1.9597 of 5 stars$43.40-3.5%$60.00+38.2%+1,072.6%$275.00MN/A-12.4710Upcoming EarningsVORVor Biopharma0.6127 of 5 stars$2.42+10.0%N/AN/A$274.91MN/A-1.60140News CoverageShort Interest ↑Gap UpACBAurora Cannabis0.3564 of 5 stars$4.78-1.2%N/A-24.1%$272.23M$246.72M43.451,130Upcoming EarningsCRDFCardiff Oncology1.9423 of 5 stars$3.73-6.0%$11.70+213.7%+17.9%$264.11M$587K-4.0520Trending NewsEarnings ReportInsider TradeOptions VolumeAnalyst RevisionGap UpEDITEditas Medicine3.9584 of 5 stars$2.96-6.0%$4.70+58.8%-51.2%$263.70M$32.31M-0.97230News CoverageUpcoming EarningsZYBTZhengye BiotechnologyN/A$5.75+3.6%N/AN/A$261.77M$25.53M0.00278News CoverageAnalyst Upgrade Related Companies and Tools Related Companies MREO Competitors TKNO Competitors ANNX Competitors LFCR Competitors MNPR Competitors VOR Competitors ACB Competitors CRDF Competitors EDIT Competitors ZYBT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNOV) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNOV Stock Alerts